BioNTech SE
BNTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001776985
In the last 90 days, BioNTech SE insiders filed 0 open-market purchases and 8 sales; 283 institutions reported holding it in 13F filings for Q2 2026, worth $4.36B in total; ARK Invest is the only superinvestor holding it.
Holders of 5% or more of BNTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of BioNTech SE, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Medine GmbH | 13G/A | 17.60%42.2M shares | – | May 13, 20251 filing | May 13, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
1 Schedule 13D or 13G filing on BioNTech SE, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 13, 20256:14 PM ET | Medine GmbHand 1 other | 13G/A | 17.60%42.2M shares | – | Mar 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell BioNTech SE shares.
No Form 144 notices for BioNTech SE are on file.